Bank of New York Mellon Corp bought a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 40,268 shares of the company's stock, valued at approximately $701,000. Bank of New York Mellon Corp owned approximately 0.07% of Bicara Therapeutics as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Spire Wealth Management acquired a new stake in shares of Bicara Therapeutics during the fourth quarter valued at about $31,000. SG Americas Securities LLC purchased a new position in Bicara Therapeutics in the fourth quarter valued at about $147,000. Cinctive Capital Management LP acquired a new stake in Bicara Therapeutics during the 3rd quarter valued at approximately $229,000. Barclays PLC purchased a new stake in Bicara Therapeutics during the 3rd quarter worth approximately $255,000. Finally, Jane Street Group LLC purchased a new stake in Bicara Therapeutics during the 3rd quarter worth approximately $309,000.
Bicara Therapeutics Stock Performance
BCAX remained flat at $13.40 on Friday. 310,531 shares of the company traded hands, compared to its average volume of 466,848. The company has a fifty day simple moving average of $13.04. Bicara Therapeutics Inc. has a 52-week low of $11.10 and a 52-week high of $28.09.
Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its earnings results on Thursday, March 27th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.08). Equities analysts anticipate that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of research firms have recently weighed in on BCAX. Wedbush reissued an "outperform" rating and set a $31.00 price target on shares of Bicara Therapeutics in a research report on Thursday. HC Wainwright raised their price objective on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the stock a "buy" rating in a report on Monday, January 27th. Finally, Cantor Fitzgerald reissued an "overweight" rating and issued a $13.01 target price on shares of Bicara Therapeutics in a research report on Thursday, March 13th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Bicara Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $36.50.
View Our Latest Report on Bicara Therapeutics
Bicara Therapeutics Profile
(
Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Further Reading
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
